German Ophthalmological Society (DOG) Honors Uta Gehlsen, PhD, with Prestigious Scientific Award for Her Research on the Use of Semifluorinated Alkanes in Dry Eye Treatment
The German Ophthalmological Society (DOG) presented Uta Gehlsen, PhD, Ocular Surface Group, Department of Ophthalmology, University of Cologne, with the “Dry Eye and Blepharitis/MGD” Award for her research related to the use of a semifluorinated alkane (SFA F4H5) as a novel carrier for cyclosporine A for the topical treatment of dry eye disease (DED).1
The DOG Awards recognize scientific and academic excellence, the advancement of young researchers, interdisciplinary and internationality in the field of ophthalmology. Sponsored by Optima Pharmazeutische GmbH, the award was presented on Saturday, September 30, 2017 during the 115th DOG Congress in Berlin.
Dr. Gehlsen’s research, which was published in Graefe’s Archive for Clinical and Experimental Ophthalmology in January 2017, found that a cyclosporine A formulation using F4H5 as its vehicle (CyclASol®, Novaliq) was equally effective but had a significantly faster therapeutic response in reducing the signs of DED compared to a commercially available treatment in an experimental mouse model.
Topical cyclosporine is a well-established medication used to treat signs of DED. It has anti-inflammatory effects and prevents T-cell activation. Clinical studies have shown that it is effective in reducing corneal staining and/or increasing tear production. Cyclosporine is also a highly lipophilic substance typically formulated as an emulsion which often causes adverse side effects with burning and stinging sensations due to the involved surfactants. The premise of the study was to learn whether a new SFA drug delivery system may improve efficacy or tolerability of cyclosporine.
“It is an honor to have been recognized by the DOG for our work in the area of SFA drug delivery technology and dry eye disease,” said Dr. Gehlsen. “Using the desiccating-stress dry-eye mouse model enables us to perform highly standardized pre-clinical in-vivo testing of topical therapies for inflammatory dry eye disease. Our experimental studies with several cyclosporine formulations hereby demonstrated a significantly faster and equally effective topical treatment effect for CyclASol® compared to other commercially available products. I am very pleased that our experimental results for CyclASol® have now been confirmed in the CYS-002 multicenter US clinical trial and hopefully will be soon available to treat patients suffering from dry eye disease.”
In this pre-clinical study, 0.05% cyclosporine dissolved in the F4H5 (CyclASol®) was found to be highly effective in reducing corneal staining and increasing tear production. Compared to the commercially available therapy comparator group, CyclASol® demonstrated at least a comparable therapeutic effect, but with a significantly faster response. Notably, early therapy with CyclASol® protected mice from developing dry eye, whereas all other study groups showed a significant increase of staining compared to baseline. CyclASol® also was the only studied treatment that demonstrated a prophylactic effect.
“On behalf of Novaliq, I congratulate Dr. Gehlsen for being presented with this award by the prestigious German Ophthalmological Society,” said Christian Roesky, PhD, managing director and CEO, Novaliq GmbH. “Through their research, we are better able to understand the many benefits of the SFA vehicle when added to traditionally insoluble or unstable drugs such as cyclosporine. Equipped with this knowledge, Novaliq has developed a very exciting and robust dry eye pipeline that has the potential to address significant unmet medical needs.”
About CyclASol ® – CyclASol® is a clear, preservative-free ophthalmic solution of cyclosporine A formulated using Novaliq’s proprietary EyeSol® drug delivery technology.
About Novaliq – Novaliq GmbH, founded in 2007, is a Heidelberg based specialty pharmaceutical company focused on ophthalmology. Its mission is to transform poorly soluble drugs into effective ocular therapeutics for both the front and the back of the eye. Novaliq’s proprietary EyeSol ® technology enhances the topical bio-availability, stability and safety of traditionally insoluble or unstable drugs improving the delivery, efficacy and convenience of treatments for ocular surface diseases including dry eye through preservative free and multi dose formulations. Novaliq has developed a tiered and long-term sustainable dry eye family of truly differentiated products that addresses the different needs of dry eye patients. Novaliq’s most advanced product is NovaTears® with CE-approval marketed under the brand name EvoTears® in Europe. CyclASol ® a second-generation prescription drug is currently in preparation for a pivotal trial. More on www.novaliq.com.
About German Ophthalmological Society (DOG)—The DOG is the medical scientific association of ophthalmology in Germany and besides the oldest ophthalmological association in the world. It unites more than 7,000 ophthalmologists in hospitals, medical and research units. One of its main scopes is to advance scientific progress in ophthalmology and to transfer acknowledged findings into the daily routine in clinics and physicians’ practices.
References:
1. Gehlsen U, Braun T, Notara M, Krösser S,
Steven P; A semifluorinated alkane (F4H5) as novel carrier for
cyclosporine A: a promising therapeutic and prophylactic option for
topical treatment of dry eye; Graefes Arch Clin Exp Ophthalmol 2017;
255(4): 767-775
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171002005397/en/
Contact information
Novaliq GmbH
For US:
Michael O’Rourke, +1-813-323-1438
Strategic
Consultant
mrourke@novaliq.com
or
For
EU/Asia:
Heidrun Kirsch, + 49 6221 50259 243
VP Marketing
hkirsch@novaliq.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mirion to Join the U.S. Industry Program at the 69th IAEA General Conference in Vienna, Austria11.9.2025 23:39:00 EEST | Press release
Mirion, a global provider of radiation detection, measurement, analysis, and monitoring solutions to the nuclear, medical, defense, and research end markets, is honored to announce its invitation to attend the 69th International Atomic Energy Agency (IAEA) General Conference. Scheduled for September 15–19 in Vienna, Austria, this annual event brings together key stakeholders from across the globe to discuss issues critical to nuclear safety, security, and peaceful applications of nuclear technology. Representing Mirion at the General Conference will be Chairman and Chief Executive Officer Thomas Logan and Chief Financial Officer Brian Schopfer. Their presence underscores the distinguished role Mirion plays as an industry leader in nuclear measurement, radiation protection, and safety solutions, in addition to its commitment to innovation and advancing global energy solutions. “We are honored to participate in this important global gathering,” Logan said. “The IAEA plays a crucial role
René Lammers Appointed Chief Research & Innovation Officer of The Estée Lauder Companies11.9.2025 23:25:00 EEST | Press release
The Estée Lauder Companies Inc. (NYSE: EL) today announced the appointment of René Lammers, Ph.D. as Executive Vice President, Chief Research & Innovation Officer, effective October 1, 2025. Mr. Lammers will report directly to Stéphane de La Faverie, President and Chief Executive Officer, and will join the company’s Executive Team. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250911004836/en/ René Lammers, Ph.D., Executive Vice President, Chief Research & Innovation Officer “René is an exceptional and innovative leader whose deep scientific expertise, global perspective, and passion for cutting-edge product development will be instrumental as we transform our approach to research and innovation to more fully align with our focus on consumer centricity,” said Mr. de La Faverie. “Creating transformative innovation is integral to our strategic vision of Beauty Reimagined, and with René’s leadership, we are elevating our capab
RTL Luxembourg Expands Deployment of Verimatrix Technologies to Protect Premier Auto Racing Against Piracy11.9.2025 18:45:00 EEST | Press release
Regulatory News: Verimatrix, (Euronext Paris: VMX), a leading provider of security solutions for a safer connected world, today announced that RTL Luxembourg, the country’s leading media company, has further expanded its use of Verimatrix anti-piracy tools to now include the full Streamkeeper suite of solutions. Initially deploying Streamkeeper Multi-DRM, RTL Luxembourg also recently implemented Counterspy, Deepscan and Watermarking solutions – the industry’s latest set of powerful tools that help further bolster proactive protections for RTL’s motorsport content revenue. It was announced in April 2024 that RTL Luxembourg selected Verimatrix Streamkeeper Multi-DRM to ensure that RTL Luxembourg remained in full control of its valuable digital assets while also consistently keeping costs low and preventing unneeded technical complexities. With the addition of Verimatrix’s Counterspy, RTL Luxembourg further expands its ability to detect unauthorized content distribution in real-time, depl
Xylem and Amazon Partner on Smart Water Upgrades to Save More Than 1.3 Billion Liters Annually in Mexico11.9.2025 17:00:00 EEST | Press release
Residents in Mexico City and Monterrey will soon enjoy more reliable water supply as the two cities launch groundbreaking infrastructure upgrades to save over 1.3 billion liters of water a year – easing pressure from the rapid urbanization and persistent drought conditions that have strained local water systems. The two cities are working in partnership with global water technology company Xylem (NYSE: XYL) and Amazon (NASDAQ: AMZN) to deploy Xylem Vue, an advanced software platform that applies data and analytics to detect leaks, cut water losses and improve residents’ water supply. The projects are estimated to save upwards of 800 million liters of water a year in Mexico City and 560 million liters a year in Monterrey. “In a water-stressed region, where every liter counts, recovering more than a billion liters of water each year is a game-changer,” said Jaime Barba, General Manager, Xylem Vue. “Working with Amazon and the local water utilities, we are using data to give these cities
HTEC Partners with World Economic Forum11.9.2025 16:56:00 EEST | Press release
HTEC, a global digital engineering and product development company, has today announced that it has joined the World Economic Forum’s (WEF) Centre for AI Excellence. HTEC will contribute to the community through its expertise and thought leadership to help advance AI adoption and AI innovation across its core industries. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250911910448/en/ HTEC Partners with World Economic Forum to bring AI expertise to help with industry transformation and real-world outcomes WEF’s Centre for AI Excellence is bringing together leading industry organisations and experts to work together to advance the pace and positive impact AI can have in economies and societies. Its goal is to unlock transformative potential in an equitable and human-centered way, which is well aligned with HTEC’s principles and values. As an AI-first organization, HTEC blends deep engineering expertise with strategic insight.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom